Condition: Renal Cell Carcinoma (RCC) · Sponsor: Tianjin Medical University Second Hospital
This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant treatment with Toripalimab. Further differentiating patients who need adjuvant immunotherapy.
This description comes directly from the study's public registry record.
Changyi Quan · 13388067990 · 345920147@qq.com
Shimiao Zhu · 13752436539 · zhushimiao1@qq.com
Always discuss trial participation with your own doctor first.
| Changyi Quan | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07657325